Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2021-06-24 Capital/Financing Update
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT obtient un financement non dilutif de 11 millions d’euros sous forme de Prêt Garanti par l’Etat
Capital/Financing Update Classification · 99% confidence The document is explicitly titled 'COMMUNIQUÉ DE PRESSE' (Press Release) and announces a specific corporate action: obtaining 11 million euros in state-guaranteed financing ('Prêt Garanti par l'Etat'). This is a material event announcement, not a full periodic report (like 10-K or IR) or a detailed presentation (like IP). It details financing activities, which aligns best with the 'Capital/Financing Update' category. The length (6847 chars) is substantial enough to be the primary announcement itself, not just a brief notice about a report. Therefore, the classification is CAP.
2021-06-24 French
GENFIT présente de nouvelles données sur NIS4® dans la NASH à l’International Liver Congress™ ainsi qu’aux 81èmes « Scientific Sessions » de l’American Diabetes Association
Investor Presentation Classification · 95% confidence The document is a press release from GENFIT dated June 23, 2021, announcing the presentation of new data regarding its NIS4® technology at two major scientific/medical events: the International Liver Congress™ and the American Diabetes Association (ADA) Scientific Sessions. It details the titles of the posters, the abstracts, and mentions a related KOL documentary video. This type of announcement, which publicizes participation in scientific conferences and the presentation of research findings, is characteristic of an Investor Presentation (IP) or a general press release about scientific progress. Since it is a detailed announcement about research being presented at external scientific meetings, and not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a formal Audit Report (AR), the most fitting category is Investor Presentation (IP), as these materials are often used to inform investors about scientific milestones and pipeline progress. It is not a Report Publication Announcement (RPA) because it is announcing the *content* being presented, not just the publication of a company report itself.
2021-06-23 French
GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association
Investor Presentation Classification · 95% confidence The document is a press release from GENFIT announcing that it will present new data regarding its NIS4® technology at two upcoming scientific/medical events (International Liver Congress™ and ADA Scientific Sessions) in June 2021. It details the titles of the poster presentations, mentions a thought-leadership documentary, and provides context about the technology and the diseases it addresses. This format—a news announcement detailing future or recent scientific/clinical updates, often referencing presentations or publications—is characteristic of an Investor Presentation (IP) or a general press release about research findings. Since it is not a formal regulatory filing (like 10-K, AR, or ER) but rather a detailed communication aimed at investors and the scientific community about ongoing research and upcoming presentations, 'Investor Presentation' (IP) is the most fitting category, as these releases often serve as the primary communication vehicle for such updates, even if the actual presentation slides are separate. It is not a Call Transcript (CT), Earnings Release (ER), or a formal report (10-K, IR).
2021-06-23 English
GENFIT : Assemblée Générale Mixte du 15 juin 2021 : Soutien largement majoritaire à ce stade pour les résolutions soumises à l’approbation des actionnaires, mais quorum insuffisant sur première convoc
AGM Information Classification · 99% confidence The document text is a press release titled 'GENFIT : Assemblée Générale Mixte du 15 juin 2021 : Soutien largement majoritaire à ce stade pour les résolutions soumises à l'approbation des actionnaires, mais quorum insuffisant sur première convocation'. It discusses the results of a shareholder meeting (Assemblée Générale Mixte), the failure to meet quorum on the first call, and the rescheduling of the meeting. It also mentions voting procedures and the composition of the meeting bureau. This content directly relates to the formal proceedings and materials associated with an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). It is not a full 10-K, an earnings release, or a proxy statement (DEF 14A/PSI), but rather an announcement regarding the AGM process itself.
2021-06-15 French
GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening
AGM Information Classification · 99% confidence The document explicitly discusses the 'Combined Shareholders Meeting' (AGM), noting that the quorum was not met on the first convening and that the meeting will be reconvened on June 30, 2021, with the same agenda. It details voting procedures, the agenda, and the composition of the meeting committee. This content directly relates to the proceedings and materials associated with the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R).
2021-06-15 English
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
AGM Information Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and its primary subject is informing shareholders about the procedures for participating in the "Combined General Meeting of June 15, 2021." It details how voting will occur (via VOTACCESS), that the meeting will be held behind closed doors, and provides broadcast details. This content directly relates to the logistics and organization of a shareholder meeting, which aligns perfectly with the definition of AGM Information (AGM-R). While it is a press release, its specific content focuses on the AGM procedures rather than just announcing the release of a report (RPA) or general regulatory news (RNS).
2021-05-27 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.